MPT: Sapien Saved Health $$$ in Intermediate-Risk TAVR

ACC Conference Reporter

TCT 2017 | DENVER — Transcatheter aortic valve replacement (TAVR) for intermediate-risk patients was cost-effective, and probably cost-saving, compared to surgery when post-procedural expenses were considered, a Medicare-linked analysis of clinical trial participants showed. Read More >>>

Keywords: Transcatheter Cardiovascular Therapeutics, TCT17

< Back to Listings